Senex Biotechnology
Senex Biotechnology is a drug discovery and development company focused on cancer therapeutics. The company develops highly selective small-molecule inhibitors targeting proteins involved in gene regulation, aiming to treat incurable cancers such as prostate, breast, and leukemia, as well as exploring applications in inflammation and cardiovascular diseases. Their latest drug candidate is anticipated to enter clinical trials within a year. The company also develops drugs targeting other cancer-specific proteins and pathways.
Industries
Nr. of Employees
small (1-50)
Senex Biotechnology
Coker Life Science Building, Room 710, 715 Sumter Street, Columbia, SC 29208
Patents
Bicyclic pyridine compositions and methods of using the same for cancer therapy
US-11572369-B2
View DetailsCDK8-CDK19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer
US-10993945-B2
View DetailsCDK8-CDK19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer
US-9321737-B2
View Details
Bicyclic pyridine compositions and methods of using the same for cancer therapy
US-11572369-B2
View DetailsCDK8-CDK19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer
US-10993945-B2
View DetailsCDK8-CDK19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer
US-9321737-B2
View DetailsProducts
Selective small-molecule Mediator kinase (CDK8/19) inhibitors
Chemically optimized selective small-molecule inhibitors targeting Mediator-associated kinases involved in transcriptional reprogramming; developed for oncology indications with demonstrated preclinical activity across breast, prostate, colon cancers and leukemias.
Selective CDK3 small-molecule inhibitors
Discovery and ongoing chemical optimization of selective inhibitors targeting CDK3, a CDK-family transcriptional regulator that is upregulated in multiple tumors and dispensable in many normal tissues.
COPZ1-targeting coatomer inhibitors
Development of selective small-molecule inhibitors targeting COPZ1-dependent coatomer function to exploit tumor-specific loss of redundant genes and selectively kill tumor cells, including non-proliferating/quiescent tumor cells.
Selective small-molecule Mediator kinase (CDK8/19) inhibitors
Chemically optimized selective small-molecule inhibitors targeting Mediator-associated kinases involved in transcriptional reprogramming; developed for oncology indications with demonstrated preclinical activity across breast, prostate, colon cancers and leukemias.
Selective CDK3 small-molecule inhibitors
Discovery and ongoing chemical optimization of selective inhibitors targeting CDK3, a CDK-family transcriptional regulator that is upregulated in multiple tumors and dispensable in many normal tissues.
COPZ1-targeting coatomer inhibitors
Development of selective small-molecule inhibitors targeting COPZ1-dependent coatomer function to exploit tumor-specific loss of redundant genes and selectively kill tumor cells, including non-proliferating/quiescent tumor cells.
Services
Discovery and chemical optimization of selective small-molecule inhibitors against oncology targets, including medicinal chemistry and pharmacokinetic optimization.
Preclinical program execution and GMP production of a clinical-stage small-molecule candidate in preparation for early-phase clinical trials.
Negotiation and management of licensing agreements and strategic collaborations to advance therapeutic candidates into external territories or co-development programs.
Discovery and chemical optimization of selective small-molecule inhibitors against oncology targets, including medicinal chemistry and pharmacokinetic optimization.
Preclinical program execution and GMP production of a clinical-stage small-molecule candidate in preparation for early-phase clinical trials.
Negotiation and management of licensing agreements and strategic collaborations to advance therapeutic candidates into external territories or co-development programs.
Expertise Areas
- Cancer drug discovery
- Small-molecule medicinal chemistry
- Functional genomics target discovery
- Preclinical development and translational research
Key Technologies
- Small-molecule medicinal chemistry
- Functional genomics screening
- Kinome profiling
- Cell-based bioassays for inhibitor activity
News & Updates
In November 2024, a key paper was published in PNAS describing the effects of Mediator kinase inhibitors on triple-negative breast cancer growth and drug resistance.
In October 2024, the company announced a patent allowance for its CDK8/19 inhibitors.
Published in the Journal of Clinical Investigation in March 2024, this paper describes how Mediator kinase inhibitors can reverse resistance in prostate cancer.
A 2022 article in PNAS reports that Mediator kinase inhibitors can prevent resistance to HER2-targeting drugs in breast cancer.
In February 2023, the company was granted a patent covering the composition of matter of new Mediator kinase inhibitors.
In May 2021, a patent was granted covering a new chemical series of kinase inhibitors.
In November 2024, a key paper was published in PNAS describing the effects of Mediator kinase inhibitors on triple-negative breast cancer growth and drug resistance.
In October 2024, the company announced a patent allowance for its CDK8/19 inhibitors.
Published in the Journal of Clinical Investigation in March 2024, this paper describes how Mediator kinase inhibitors can reverse resistance in prostate cancer.
A 2022 article in PNAS reports that Mediator kinase inhibitors can prevent resistance to HER2-targeting drugs in breast cancer.
In February 2023, the company was granted a patent covering the composition of matter of new Mediator kinase inhibitors.
In May 2021, a patent was granted covering a new chemical series of kinase inhibitors.